BidaskClub Downgrades Axovant Sciences Ltd (AXON) to Sell

Axovant Sciences Ltd (NYSE:AXON) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday, October 17th.

A number of other research firms have also issued reports on AXON. Cowen and Company reiterated an “outperform” rating and issued a $30.00 target price on shares of Axovant Sciences in a research note on Wednesday, June 21st. Jefferies Group LLC initiated coverage on shares of Axovant Sciences in a research note on Monday, July 10th. They issued a “buy” rating and a $40.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Axovant Sciences in a report on Wednesday, September 27th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $30.00 price target on shares of Axovant Sciences in a report on Monday, September 25th. Finally, Evercore ISI reissued an “outperform” rating and issued a $9.00 price target (down from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $14.13.

Axovant Sciences (NYSE AXON) traded down 4.12% during trading on Tuesday, reaching $4.89. The company had a trading volume of 682,565 shares. Axovant Sciences has a 1-year low of $4.60 and a 1-year high of $27.98. The firm has a 50-day moving average of $12.67 and a 200-day moving average of $19.75. The stock’s market capitalization is $525.80 million.

Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, analysts anticipate that Axovant Sciences will post ($2.02) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/axovant-sciences-ltd-axon-downgraded-by-bidaskclub-to-sell.html.

Several large investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Axovant Sciences by 1.6% during the 2nd quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 355 shares during the period. American International Group Inc. lifted its holdings in shares of Axovant Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 998 shares during the period. Legal & General Group Plc lifted its holdings in Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 1,168 shares during the last quarter. Bank of America Corp DE lifted its holdings in Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 2,072 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Axovant Sciences by 38.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 2,789 shares during the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply